A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease

Trial Profile

A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Preladenant (Primary) ; Rasagiline
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADYSE-Monotherapy
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 29 Apr 2014 Primary endpoint 'Unified-Parkinson's-Disease-Rating-Scale' has not been met.
    • 19 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top